ORTHOFIX MEDICAL INC. (OFIX), a Delaware corporation trading on NASDAQ, filed an 8-K on November 4, 2025, reporting Q3 2025 financial results based on pro forma reporting which excludes discontinued M6 product lines.
Q3 2025 Financial Highlights (Pro Forma): Net Sales reached $203.4 million, representing 6% constant currency growth. Adjusted EBITDA was $24.6 million (12.1% margin), marking the seventh consecutive quarter of margin expansion. The company achieved positive Free Cash Flow of $2.5 million for the quarter.
Operational Drivers: Performance was strong across key segments
...